Octreotide for Pediatric Variceal Bleeding: Very Low Certainty Evidence

This systematic review consolidates the sparse pediatric data on off-label octreotide for portal hypertension-related gastrointestinal bleeding, informing how pharmacists counsel prescribers on dosing, monitoring, and evidentiary limits.

📅 Journal publication: Jun 24, 2026 · Last updated: Oct 7, 2026

octreotidesomatostatin analogportal hypertensionvariceal bleedinggastrointestinal hemorrhagepediatricssystematic reviewoff-labeldrug repurposinghyperglycemia Pediatric Pharmacy

Also in Gastroenterology / Hepatology

Background Information

Octreotide shows potential in managing pediatric GI bleeding from portal hypertension.

Octreotide is increasingly used off-label for gastrointestinal (GI) bleeding due to portal hypertension in children, but evidence-based guidelines are lacking. The review included 33 children; octreotide reduced bleeding episodes and transfusion needs in some cases, with mild and reversible hyperglycemia as the only reported side effect. Due to high risk of bias and heterogeneity in data, current evidence is very low certainty; more research is needed to confirm efficacy and safety for long-term use. Octreotide could be promising for pediatric GI bleeding due to portal hypertension, but its role needs further validation.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kozak A, Nolder G, Ranucci G, Provenzani A

Citation: Kozak A, Nolder G, Ranucci G, et al. Efficacy and Safety of Octreotide for Gastrointestinal Bleeding Due to Portal Hypertension in Children-A Systematic Review. Pharmaceuticals (Basel, Switzerland). 2026;19(7). doi:10.3390/ph19070978

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →